Beckman Coulter Diagnostics and COPAN Announce Expansion of Distribution Agreement
News Aug 12, 2015
Beckman Coulter Diagnostics and COPAN have announced that Beckman Coulter Diagnostics and COPAN Group have entered into an amendment to their distribution agreement that expands their relationship into new products and geographic territories.
Additional products include COPAN’s WASPLab automated, front‐end robotic specimen processing, full lab automation and digital microbiology system. The amendment grants Beckman Coulter distribution rights in 21 global markets, including a number of territories in North America, Asia (including, among other territories, Japan and China), Europe, South America and many emerging markets.
“We’re very excited to expand our relationship with COPAN to offer clinical microbiology
laboratories an extended portfolio of products to help provide physicians with the critical information they need regarding bacteria resistance,” said Arnd Kaldowski, president, Beckman Coulter Diagnostics.
Kaldowski continued, “COPAN’s products complement our newly acquired MicroScan brand of microbiology solutions and offer hospitals and private laboratories a complete solution which streamlines workflow—demonstrating Beckman Coulter’s commitment to growth and investment in this new area of our business.”
Stefania Triva, COPAN Group’s CEO said, “This is a new step in the collaboration between the two companies and we look forward to continue working together to expand our reach.” Norman Sharples, Executive VP and Co‐Founder of COPAN Diagnostics, Inc. added, “COPAN has always been committed to provide open platform solutions to our customers and this partnership is further evidence and reinforcement of our ability to integrate and interface with important platforms in microbiology.”
In addition to WASPLab, the amendment allows Beckman Coulter to distribute COPAN’s CTracer, SYNAPSEPro MINI and MALDI‐Trace products.
Test For Designer Drugs Could Help Treat Overdose PatientsNews
Medical professionals are scrambling to meet the growing demand for emergency room treatment, but they’re hampered by the lack of a quick and easy test to screen patients for “designer” drugs. Chemists have now developed such a test and are refining it with the hope that hospitals could eventually use it to choose the appropriate treatment.READ MORE
Cancer ‘Signature’ First Step Toward Blood Test for PatientsNews
A discovery by Melbourne researchers could help to identify patients with a particularly aggressive type of lung cancer that are likely to respond to immunotherapies currently used in the clinic to treat other cancers.READ MORE
Comments | 0 ADD COMMENT
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018
World Congress on Plant Science and Molecular Biology
Sep 12 - Sep 13, 2018